269 related articles for article (PubMed ID: 3220118)
21. Chronic haloperidol does not alter agonist affinity for dopamine receptors in vitro.
Meller E; Bohmaker K; Goldstein M; Schweitzer JW; Friedhoff AJ
Eur J Pharmacol; 1985 Mar; 109(3):389-94. PubMed ID: 3157587
[TBL] [Abstract][Full Text] [Related]
22. Decrease in the evoked release of endogenous dopamine and dihydroxyphenylacetic acid from rat striatal slices after withdrawal from repeated haloperidol.
Umeda Y; Sumi T
Eur J Pharmacol; 1990 Nov; 191(2):149-55. PubMed ID: 2086236
[TBL] [Abstract][Full Text] [Related]
23. Relationship between dopamine receptor occupation by spiperone and acetylcholine levels in the rat striatum after long-term haloperidol treatment depends on dopamine innervation.
Korf J; Sebens JB
J Neurochem; 1987 Feb; 48(2):516-21. PubMed ID: 2878979
[TBL] [Abstract][Full Text] [Related]
24. Factors contributing to the up regulation of dopaminergic receptors by chronic haloperidol.
Schweitzer JW; Schwartz R; Friedhoff AJ
Res Commun Chem Pathol Pharmacol; 1982 Oct; 38(1):21-30. PubMed ID: 7146618
[TBL] [Abstract][Full Text] [Related]
25. Striatal dopamine metabolism in response to apomorphine: the effects of repeated amphetamine pretreatment.
Kuczenski R; Leith NJ; Applegate CD
Brain Res; 1983 Jan; 258(2):333-7. PubMed ID: 6824917
[TBL] [Abstract][Full Text] [Related]
26. Endurance training effects on striatal D2 dopamine receptor binding and striatal dopamine metabolites in presenescent older rats.
MacRae PG; Spirduso WW; Walters TJ; Farrar RP; Wilcox RE
Psychopharmacology (Berl); 1987; 92(2):236-40. PubMed ID: 3110847
[TBL] [Abstract][Full Text] [Related]
27. [Effect of repeated haloperidol and apomorphine administration on the development of tolerance for catalepsy and dopamine receptor hypersensitivity in mice].
Zharkovskiĭ AM; Matvienko OA; Nurk AM
Biull Eksp Biol Med; 1984 Oct; 98(10):444-6. PubMed ID: 6541951
[TBL] [Abstract][Full Text] [Related]
28. Different plasticity changes in D1 and D2 receptors in rat striatal subregions following impairment of dopaminergic transmission.
Savasta M; Dubois A; Benavidès J; Scatton B
Neurosci Lett; 1988 Feb; 85(1):119-24. PubMed ID: 2834672
[TBL] [Abstract][Full Text] [Related]
29. SCH 23390 may alter dopamine-mediated motor behaviour via striatal D-1 receptors.
Boyce S; Kelly E; Davis A; Fleminger S; Jenner P; Marsden CD
Biochem Pharmacol; 1985 May; 34(10):1665-9. PubMed ID: 2988552
[TBL] [Abstract][Full Text] [Related]
30. Reserpine-induced up-regulation of dopamine D2 receptors in the rat striatum is enhanced by denervation but not by chronic receptor blockade.
Traub M; Reches A; Wagner HR; Fahn S
Neurosci Lett; 1986 Oct; 70(2):245-9. PubMed ID: 2946007
[TBL] [Abstract][Full Text] [Related]
31. Effects of systemic and intracerebroventricular domperidone treatment on striatal and hypothalamic dopaminergic neurons.
Ferretti C; Benfenati F; Cimino M; Vantini G; Lipartiti M; Muccioli G; di Carlo R; Algeri S
Med Biol; 1983; 61(6):331-6. PubMed ID: 6676604
[TBL] [Abstract][Full Text] [Related]
32. Rapid conversion of high into low striatal D2-dopamine receptor agonist binding states after an acute physiological dose of 17 beta-estradiol.
Lévesque D; Di Paolo T
Neurosci Lett; 1988 May; 88(1):113-8. PubMed ID: 2969467
[TBL] [Abstract][Full Text] [Related]
33. Dopamine denervation does not alter in vivo 3H-spiperone binding in rat striatum: implications for external imaging of dopamine receptors in Parkinson's disease.
Bennett JP; Wooten GF
Ann Neurol; 1986 Apr; 19(4):378-83. PubMed ID: 3707090
[TBL] [Abstract][Full Text] [Related]
34. Aging process affects a single class of dopamine receptors.
Memo M; Lucchi L; Spano PF; Trabucchi M
Brain Res; 1980 Dec; 202(2):488-92. PubMed ID: 7437912
[TBL] [Abstract][Full Text] [Related]
35. Differential effects of chronic clorgyline and amfonelic acid on desensitization of striatal dopamine receptors.
Meller E; Bohmaker K; Friedhoff AJ
Life Sci; 1984 Oct; 35(18):1829-38. PubMed ID: 6492992
[TBL] [Abstract][Full Text] [Related]
36. Developmental change in striatal concentration of homovanillic acid and 3,4-dihydroxyphenylacetic acid in response to apomorphine and haloperidol treatment.
Nomura Y; Komori T; Okuda S; Segawa T
Arch Int Pharmacodyn Ther; 1979 Jan; 237(1):25-30. PubMed ID: 485682
[TBL] [Abstract][Full Text] [Related]
37. Haloperidol: effect of long-term treatment on rat striatal dopamine synthesis and turnover.
Lerner P; Nosé P; Gordon EK; Lovenberg W
Science; 1977 Jul; 197(4299):181-3. PubMed ID: 17917
[TBL] [Abstract][Full Text] [Related]
38. On the mechanism of mergocryptine-induced suppression of dopamine turnover in the rat striatum.
Hashimoto T; Katsura M; Kuriyama K
Eur J Pharmacol; 1991 Jun; 198(2-3):121-7. PubMed ID: 1864302
[TBL] [Abstract][Full Text] [Related]
39. Differential effects of continuous administration for 1 year of haloperidol or sulpiride on striatal dopamine function in the rat.
Rupniak NM; Mann S; Hall MD; Fleminger S; Kilpatrick G; Jenner P; Marsden CD
Psychopharmacology (Berl); 1984; 84(4):503-11. PubMed ID: 6441951
[TBL] [Abstract][Full Text] [Related]
40. Relation between brain dopamine loss and D2 dopamine receptor density in MPTP monkeys.
Falardeau P; Bédard PJ; Di Paolo T
Neurosci Lett; 1988 Mar; 86(2):225-9. PubMed ID: 2966905
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
